Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder.

MLA

Stastna, D., et al. “Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in AntiCD20‑treated Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.” Multiple Sclerosis and Related Disorders, vol. 85, May 2024, p. 105523. EBSCOhost, https://doi.org/10.1016/j.msard.2024.105523.

APA

Stastna, D., Vachova, M., Dusek, P., Fistravec, G., Drahota, J., Menkyova, I., Varju, E., Horakova, D., Kubala Havrdova, E., & Nytrova, P. (2024). Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 85, 105523. https://doi.org/10.1016/j.msard.2024.105523

Chicago

Stastna, D, M Vachova, P Dusek, G Fistravec, J Drahota, I Menkyova, E Varju, D Horakova, E Kubala Havrdova, and P Nytrova. 2024. “Effectiveness of Tixagevimab/Cilgavimab (Evusheld) in AntiCD20‑treated Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.” Multiple Sclerosis and Related Disorders 85 (May): 105523. doi:10.1016/j.msard.2024.105523.